newsfilter
← Latest News
GlobeNewswire·

Checkmate Pharmaceuticals Presents Final Clinical Data for Phase 1b Study Evaluating Vidutolimod at The Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

Vidutolimod in combination with pembrolizumab demonstrated promising clinical activity in patients with PD-1 blockade-refractory melanoma with an ORR of 23.5% per RECIST v1.1 Vidutolimod also demonstrated monotherapy activity with an ORR of 20.0% pe